Caroline Ségaut-Prévost

Three-year safety results of SAR422459 (EIAV-ABCA4) gene therapy in patients with ABCA4-associated Stargardt disease: An open-label dose-escalation phase I/IIa clinical trial, cohorts 1-5.

David J. Wilson, Elvira N. Chegarnov, J. Sahel, 2022, American journal of ophthalmology.